TransCode Therapeutics to Host R&D Webcast as It Advances Phase 2a Trial for Colorectal Cancer
TransCode Therapeutics will provide strategic and clinical updates during its first live R&D webcast, anchored by its Phase 2a trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer, highlighting progress in RNA-based oncology treatments.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced it will host its first live virtual R&D webcast on June 18, 2026, to provide strategic, scientific and clinical updates across its development pipeline. The presentation will be anchored by the company’s recently initiated Phase 2a clinical trial of TTX-MC138 in circulating tumor DNA-positive colorectal cancer and will also include portfolio updates and discussion of its broader investment thesis.
The webcast represents a key milestone for the clinical-stage company, which is pioneering immuno-oncology and RNA therapeutic treatments for high risk and advanced cancers. TransCode’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique and well-documented biomarker of metastasis. The initiation of the Phase 2a trial marks a significant step forward in validating this approach.
According to the company, the webcast will offer investors and stakeholders a comprehensive look at the progress of its pipeline, including updates on other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The event underscores TransCode’s commitment to transparency and engagement with the investment community as it advances its clinical programs.
For more details, the full press release is available at https://ibn.fm/u5AfW. The latest news and updates relating to RNAZ can be found in the company’s newsroom at https://ibn.fm/RNAZ.
The importance of this announcement lies in the potential of TTX-MC138 to address a critical unmet need in oncology: treating metastatic tumors that have spread from primary sites. Colorectal cancer remains one of the leading causes of cancer-related deaths worldwide, and the ability to target circulating tumor DNA-positive patients could enable earlier intervention and more personalized treatment strategies. The Phase 2a trial will provide crucial data on the safety and efficacy of this RNA-based therapy.
TransCode’s broader portfolio includes other candidates that aim to harness the immune system against cancer, reflecting a growing trend in oncology toward combination therapies that attack tumors through multiple mechanisms. The R&D webcast will likely shed light on how these programs fit together and the company’s strategic priorities moving forward.
Investors should note that the webcast comes at a time when RNA therapeutics are gaining traction, following the success of mRNA vaccines and increased interest in targeting non-coding RNAs like microRNA-10b. If successful, TTX-MC138 could become a first-in-class treatment for metastatic cancers, potentially opening up a new market in oncology.